CoChat

Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms

Open access
Molenaar, R J, Thota, S, Nagata, Y, Patel, B, Clemente, M, Przychodzen, B, Hirsh, C, Viny, A D, Hosano, N, Bleeker, F E, Meggendorfer, M, Alpermann, T, Shiraishi, Y, Chiba, K, Tanaka, H, van Noorden, C J F, Radivoyevitch, T, Carraway, H E, Makishima, H, Miyano, S, Sekeres, M A, Ogawa, S, Haferlach, T, Maciejewski, J P · 2015 · Leukemia
Cited by 94

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Mutations in isocitrate dehydrogenase 1/2 (IDH1/2MT) are drivers of a variety of myeloid neoplasms. As they yield the same oncometabolite, D-2-hydroxyglutarate, they are often treated as equivalent, and pooled. We studied the validity of this approach and found IDH1/2 mutations in 179 of 2119 myeloid neoplasms (8%). Cross-sectionally, the frequencies of these mutations increased from lower- to higher risk disease, thus suggesting a role in clinical progression. Variant allelic frequencies indicated that IDH1MT and IDH2MT are ancestral in up to 14/74 (19%) vs 34/99 (34%; P=0.027) of cases, respectively, illustrating the pathogenic role of these lesions in myeloid neoplasms. IDH1/2MT was associated with poor overall survival, particularly in lower risk myelodysplastic syndromes. Ancestral IDH1MT cases were associated with a worse prognosis than subclonal IDH1MT cases, whereas the position of IDH2MT within clonal hierarchy did not impact survival. This may relate to distinct mutational spectra with more DNMT3A and NPM1 mutations associated with IDH1MT cases, and more ASXL1, SRSF2, RUNX1, STAG2 mutations associated with IDH2MT cases. Our data demonstrate important clinical and biological differences between IDH1MT and IDH2MT myeloid neoplasms. These mutations should be considered separately as their differences could have implications for diagnosis, prognosis and treatment with IDH1/2MT inhibitors of IDH1/2MT patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/leu.2015.91

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 94

Metadata

Authors
Molenaar, R. J., Thota, S., Nagata, Y., Patel, B., Clemente, M., Przychodzen, B., Hirsh, C., Viny, A. D., Hosano, N., Bleeker, F. E., Meggendorfer, M., Alpermann, T., Shiraishi, Y., Chiba, K., Tanaka, H., van Noorden, C. J. F., Radivoyevitch, T., Carraway, H. E., Makishima, H., Miyano, S., Sekeres, M. A., Ogawa, S., Haferlach, T., & Maciejewski, J. P.
Venue
Leukemia
Published
2015-04-03
Volume
29
Issue
11
Pages
2134-2142
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W2075017638
Cited by
94
References
18
FWCI
6.56
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. https://app.cochat.ai/papers/10.1038/leu.2015.91
The paper
Molenaar, R. J., Thota, S., Nagata, Y., Patel, B., Clemente, M., Przychodzen, B., Hirsh, C., Viny, A. D., Hosano, N., Bleeker, F. E., Meggendorfer, M., Alpermann, T., Shiraishi, Y., Chiba, K., Tanaka, H., van Noorden, C. J. F., Radivoyevitch, T., Carraway, H. E., Makishima, H., . . . Maciejewski, J. P. (2015). Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. Leukemia. https://doi.org/10.1038/leu.2015.91

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.